Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $39.20

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) have been given a consensus rating of “Buy” by the seven research firms that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $39.20.

A number of research analysts have issued reports on the company. Wells Fargo & Company upgraded Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $12.00 to $35.00 in a research note on Friday, March 1st. Stifel Nicolaus boosted their price objective on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th.

Spyre Therapeutics Price Performance

Shares of NASDAQ SYRE opened at $33.56 on Tuesday. The company’s fifty day moving average price is $34.92. The stock has a market cap of $1.21 billion, a PE ratio of -0.45 and a beta of 2.88. Spyre Therapeutics has a one year low of $2.66 and a one year high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($0.48) by ($1.80). As a group, research analysts forecast that Spyre Therapeutics will post -2.36 earnings per share for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).